These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 33191195)

  • 1. Chronic kidney disease and statin eligibility.
    Vega GL; Wang J; Grundy SM
    J Clin Lipidol; 2021; 15(1):173-180. PubMed ID: 33191195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atherosclerotic Cardiovascular Disease Risk Estimates Using the Predicting Risk of Cardiovascular Disease Events Equations.
    Anderson TS; Wilson LM; Sussman JB
    JAMA Intern Med; 2024 Aug; 184(8):963-970. PubMed ID: 38856978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Coronary Artery Calcium Scoring to Guide Statin Therapy Allocation According to Risk-Enhancing Factors: The Multi-Ethnic Study of Atherosclerosis.
    Patel J; Pallazola VA; Dudum R; Greenland P; McEvoy JW; Blumenthal RS; Virani SS; Miedema MD; Shea S; Yeboah J; Abbate A; Hundley WG; Karger AB; Tsai MY; Sathiyakumar V; Ogunmoroti O; Cushman M; Savji N; Liu K; Nasir K; Blaha MJ; Martin SS; Al Rifai M
    JAMA Cardiol; 2021 Oct; 6(10):1161-1170. PubMed ID: 34259820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in Statin Use Among US Adults With Chronic Kidney Disease, 1999-2014.
    Mefford MT; Rosenson RS; Deng L; Tanner RM; Bittner V; Safford MM; Coll B; Mues KE; Monda KL; Muntner P
    J Am Heart Assoc; 2019 Jan; 8(2):e010640. PubMed ID: 30651020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology/American Heart Association Cholesterol Management Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Nasir K; Bittencourt MS; Blaha MJ; Blankstein R; Agatson AS; Rivera JJ; Miedema MD; Sibley CT; Shaw LJ; Blumenthal RS; Budoff MJ; Krumholz HM
    J Am Coll Cardiol; 2015 Oct; 66(15):1657-68. PubMed ID: 26449135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subclinical Atherosclerosis, Statin Eligibility, and Outcomes in African American Individuals: The Jackson Heart Study.
    Shah RV; Spahillari A; Mwasongwe S; Carr JJ; Terry JG; Mentz RJ; Addison D; Hoffmann U; Reis J; Freedman JE; Lima JAC; Correa A; Murthy VL
    JAMA Cardiol; 2017 Jun; 2(6):644-652. PubMed ID: 28315622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Statin Use for Primary Prevention of Atherosclerotic Cardiovascular Disease by Race, Ethnicity, and 10-Year Disease Risk in the US: National Health and Nutrition Examination Surveys, 2013 to March 2020.
    Jacobs JA; Addo DK; Zheutlin AR; Derington CG; Essien UR; Navar AM; Hernandez I; Lloyd-Jones DM; King JB; Rao S; Herrick JS; Bress AP; Pandey A
    JAMA Cardiol; 2023 May; 8(5):443-452. PubMed ID: 36947031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
    Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
    Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD.
    Bajaj A; Xie D; Cedillo-Couvert E; Charleston J; Chen J; Deo R; Feldman HI; Go AS; He J; Horwitz E; Kallem R; Rahman M; Weir MR; Anderson AH; Rader DJ;
    Am J Kidney Dis; 2019 Jun; 73(6):827-836. PubMed ID: 30686529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin Eligibility for Primary Prevention of Cardiovascular Disease According to 2021 European Prevention Guidelines Compared With Other International Guidelines.
    Mortensen MB; Tybjærg-Hansen A; Nordestgaard BG
    JAMA Cardiol; 2022 Aug; 7(8):836-843. PubMed ID: 35793078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statin Eligibility, Coronary Artery Calcium, and Subsequent Cardiovascular Events According to the 2016 United States Preventive Services Task Force (USPSTF) Statin Guidelines: MESA (Multi-Ethnic Study of Atherosclerosis).
    Miedema MD; Dardari ZA; Kianoush S; Virani SS; Yeboah J; Knickelbine T; Sandfort V; Rodriguez CJ; Nasir K; Blaha MJ
    J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29899017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implications of the 2019 American College of Cardiology/American Heart Association Primary Prevention Guidelines and potential value of the coronary artery calcium score among South Asians in the US: The Mediators of Atherosclerosis in South Asians Living in America (MASALA) study.
    Haque W; Grandhi GR; Kanaya AM; Kandula NR; Nasir K; Al Rifai M; Uddin SMI; Fedeli U; Sattar N; Blumenthal RS; Blaha MJ; Cainzos-Achirica M
    Atherosclerosis; 2021 Oct; 334():48-56. PubMed ID: 34481175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between intensity of statin therapy and mortality in persons with chronic kidney disease.
    Walther CP; Richardson PA; Virani SS; Winkelmayer WC; Navaneethan SD
    Nephrol Dial Transplant; 2020 Feb; 35(2):312-319. PubMed ID: 30053252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing eligibility for statin therapy for primary prevention under 2022 USPSTF recommendations and the 2018 AHA/ACC/ multi-society guideline recommendations: From National Health and Nutrition Examination Survey.
    Gupta K; Kakar TS; Jain V; Gupta M; Al Rifai M; Slipczuk L; Nambi V; Bittner V; Blumenthal RS; Stone NJ; Lavie CJ; Virani SS
    Prog Cardiovasc Dis; 2022; 75():78-82. PubMed ID: 36038004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
    Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
    JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
    Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
    Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.